April 07, 2020
The Patent Trial and Appeal Board said in a precedential decision Tuesday that the rules for determining whether a printed publication was publicly available and can be used to invalidate a patent are different during patent examination than in inter partes reviews.
March 23, 2017
The Patent Trial and Appeal Board upheld a Research Corp. Technologies Inc. patent for the anti-epileptic drug Vimpat on Wednesday, just months after a Delaware federal judge refused to invalidate part of the patent in an infringement suit brought against generic-drug makers.
May 24, 2016
The Patent Trial and Appeal Board on Monday accepted generic drugmaker Argentum Pharmaceuticals' petition to review a patent for UCB Inc.'s epilepsy drug Vimpat.